secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001213900-25-125413
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025
-------------------------------------------------------------------------------

- Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.
- R&D expenses $9.2M vs $11.9M YoY; G&A $18.5M vs $18.2M YoY.
- Raised ~$61M in gross proceeds: $25M at Citius Pharma, $36M at Citius Oncology (CTOR).
- LYMPHIR launched in U.S. December 2025 for CTCL; secured NCCN Category 2A and HCPCS J-code.
- Cash and equivalents $4.3M at Sep 30, 2025; continued FDA engagement on Mino-Lok and Halo-Lido.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/0001213900-25-125413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/ea0270776-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-125413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer